Scilex Holding (SCLXW) Other Operating Expenses (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Other Operating Expenses of -$18.1 million in Q1 2026, down 7.0% quarter-over-quarter from -$16.9 million in Q4 2025.
Scilex Holding (SCLXW) Other Operating Expenses (2020 - 2026) Analysis & Trends
Scilex Holding's Other Operating Expenses history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.
- In Q1 2026, Other Operating Expenses changed N/A year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at -$25.9 million (down 579.86% YoY), while the FY2025 annual figure was -$12.2 million, changed N/A from the prior year.
- Other Operating Expenses was -$18.1 million for Q1 2026 at Scilex Holding, down from -$16.9 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $5.5 million in Q4 2023 to a low of -$18.1 million in Q1 2026.
- Historically, Other Operating Expenses has averaged $418558.1 across 5 years, with a median of $4.4 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Other Operating Expenses jumped 4961.73% in 2022, then tumbled 143.83% in 2024.
- A 5-year view of Other Operating Expenses shows it stood at $5.5 million in 2022, then grew by 0.14% to $5.5 million in 2023, then retreated by 2.81% to $5.4 million in 2024, then slumped by 413.15% to -$16.9 million in 2025, then slipped by 7.0% to -$18.1 million in 2026.
- The last three Other Operating Expenses figures came in at -$18.1 million (Q1 2026), -$16.9 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.06 Mn |
| Dec 31, 2025 | -16.88 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | -2.02 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 4.42 Mn |
| Jun 30, 2023 | 5.20 Mn |
| Mar 31, 2023 | 4.62 Mn |
| Dec 31, 2022 | 5.54 Mn |
| Sep 30, 2022 | 526,359.00 |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | -485,807.00 |
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | -1.16 Mn |
| Jun 30, 2021 | -61,609.00 |
| Mar 31, 2021 | 1.49 Mn |
| Dec 31, 2020 | 6,276.00 |
| Sep 30, 2020 | 856.00 |